A new study has compared a range of composite measures used for assessing disease activity in patients with psoriatic arthritis (PsA). The measures included the Arithmetic Mean of the Desirability Function (AMDF), the Composite Psoriatic Disease Activity Index (CPDAI) and the Psoriatic Arthritis Disease Activity Score (PASDAS), with the Disease Activity Score for 28 joints (DAS28) used as a comparator. All measures were able to distinguish a response in patients with PsA who were treated with golimumab, although the PASDAS and AMDF measures, which incorporate more facets of PsA, including skin, enthesitis and dactylitis, performed better than traditional joint-only measures.